Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving ForwardCybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The HorizonPure Extracts Orders Cutting Edge Vitalis Cosolvent Injection SystemTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of PsychedelicsCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th PrRritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale ManuNuminus Wellness Is Taking Strides To Advance Its R&D Business UnitRritual Announces Successful Launch of US Facing E-Commerce Website and Provides Corporate Update

Technical420 Site Search

Returned 13 result(s).

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced plans to advance the pre-clinical work for its orally dissolving tablet ("ODT") formulation of CYB003 and its inhaled formulation of CYB004, two of the Company’s deuterated tryptamine development candidates. These studies are part…

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

-Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as…

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has signed a drug development agreement with Catalent, Inc. (NYSE:CTLT) the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer…

Cybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The Horizon

Earlier this year, Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) completed a go-public transaction on the NEO Exchange and has captured our attention. The biotechnology company is focused on advancing psychedelic therapeutics through clinical trials and we are favorable on how the story has advanced so far this year. Yesterday, Cybin announced an…

Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has completed its 20th pre-clinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. “Excellent team-work and fully supportive partners have greatly facilitated the…

Cybin Inc. Is Focused On Taking A Quantitative Approach To Tackling Depression

Earlier this month, Cybin Inc. (NEO:CYBN) issued an operational update after it reported third quarter financial results and this is an opportunity that we continue to closely follow. The biotech firm is focused on advancing psychedelic therapeutics through clinical trials and commercializing treatments for mental health disorders. We classify Cybin…

3 Psychedelic Sector Leaders That Investors Need To Be Aware Of

The last few years have been significant for the psychedelic therapy industry and we believe the sector is in not even in the first inning of a major growth cycle. From a regulatory standpoint, the psychedelic therapy industry has reported significant advancements, and this is a trend that we expect…

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Cybin Inc. (NEO:CYBN), a life sciences company focused on psychedelic therapeutics, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel to leverage its innovative technology, Kernel Flow, for its upcoming sponsored clinical work. Click here to view the accompanying film. Flow is a…

CYBIN Provides Update on Patent Filings & Development of Therapeutics Program

Cybin Inc. (NEO:CYBN) (“Cybin” or the “Company”), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to provide an update on its on its eight patent filings, which cover the Company’s novel therapeutics, delivery mechanisms and treatment regiments. Cybin’s updated corporate presentation will be available at www.cybin.com. The Company is…

Cybin Corp. Acquires Adelia Therapeutics To Bolster IP Portfolio and Human Capital

Yesterday morning, Cybin Inc. (NEO:CYBN) reported a major milestone announcing the closing of 100% of Adelia Therapeutics Inc. The transaction is transformational for Cybin’s drug development program and we are favorable on the potential that is associated with the combined company. A Transformational All-Stock Acquisition for Cybin One of the…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link